Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab Combined With Reduced-dose Chemotherapy in Precursor B-Cell ALL
NCT06742515Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete remission rate with negative minimal residual disease. Started Oct 2024; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06742515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742515.